Impact of prescription benefit coverage limits on sevelamer hydrochloride adherence for patients with ESRD

American Health and Drug Benefits

Volumn 2, Issue 6, 2009, Pages 242-250

  Bhardwaja, Bharati ^a,b   Carroll, Nikki ^a   Korner, Eli ^c   Nair, Kavita V ^b  

^a KAISER PERMANENTE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c Roche Laboratories   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

SEVELAMER;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG UTILIZATION; FEMALE; HEALTH CARE COST; HEMODIALYSIS; HUMAN; HYPERPHOSPHATEMIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEDICARE; PATIENT COMPLIANCE; PERITONEAL DIALYSIS; PILOT STUDY; PRESCRIPTION; RETROSPECTIVE STUDY;

EID: 77953379120     PISSN: 19422962     EISSN: 19422970     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Moe SM, Sprague AM. Mineral and bone disorders in chronic kidney disease. In: Brenner BM. Brenner & Rector's The Kidney. Philadelphia, PA: Saunders Elsevier; 2008.
2. Delmez JA, Slatopolsky E. Hyperphosphatemia: its consequences and treatment in patients with chronic renal disease. Am J Kidney Dis. 1992; 4:303-317.
3. Ganesh SK, Stack AG, Levin NW, et al. Association of elevated serum PO(4), Ca X PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol. 2001;12:2131-2138.
4. Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004; 15:2208-2218.
5. Block GA, Danese M, Kim K, et al. Elevated PTH and Ca X P levels are associated with increased hospitalization in hemodialysis patients. Am J Kidney Dis. 2003;41:A3. Abstract 15.
6. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium X phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998;31: 607-617.
7. Saran R, Bragg-Gresham JL, Rayner HC, et al. Nonadherence in hemodialysis: associations with mortality, hospitalization, and practice patterns in the DOPPS. Kidney Int. 2003;64:254-262.
8. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(4 suppl 3):S1-S201.
9. Bleyer AJ, Burke SK, Dillon M, et al. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis. 1999;33:694-701.
10. Block GA, Klassen P, Danese M, et al. Relationship between serum calcium and mortality risk in hemodialysis patients. Am J Kidney Dis. 2003;41:A3. Abstract 16.
11. Chertow GM, Burke SK, Raggi P, for the Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002;62:245-252.
12. Goldberg DI, Dillon MA, Slatopolsky EA, et al. Effect of RenaGel, a non-absorbed, calcium- and aluminum-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients. Nephrol Dial Transplant. 1998;13:2303-2310.
13. Slatopolsky EA, Burke SK, Dillon MA; the RenaGel Study Group. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers phosphorus and parathyroid hormone. Kidney Int. 1999;55:299-307.
14. Chertow GM. Slowing the progression of vascular calcification in hemodialysis. J Am Soc Nephrol. 2003;14(9 suppl 4):S310-S314.
15. White CA, Jaffery J, Magner P. Cost of applying the K/DOQI guidelines for bone metabolism and disease to a cohort of chronic hemodialysis patients. Kidney Int. 2007;71:312-317.
16. Goodman WG. Medical management of secondary hyperparathyroidism in chronic renal failure. Nephrol Dial Transplant. 2003;18(suppl 3):iii2-iii8.
17. Amin N. The impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure. Nephrol Dial Transplant. 2002;17:340-345.
18. 2003 Drug Topics Red Book. Montvale, NJ: Medical Economics; 2003.
19. 2004 Drug Topics Red Book. Montvale, NJ: Medical Economics; 2004.
20. Collins AJ, St. Peter WL, Dalleska FW, et al. Hospitalization risks between Renagel phosphate binder treated and non-Renagel treated patients. Clin Nephrol. 2000;54:334-341.
21. Loghman-Adham M. Medication noncompliance in patients with chronic disease: issues in dialysis and renal transplantation. Am J Manag Care. 2003;9:155-171.
22. Bame SI, Petersen N, Wray NP. Variation in hemodialysis patient compliance according to demographic characteristics. Soc Sci Med. 1993; 37:1035-1043.
23. Cleary DJ, Matzke GR, Alexander AC, Joy MS. Medication knowledge and compliance among patients receiving long-term dialysis. Am J Health Syst Pharm. 1995;52:1895-1900.
24. Hirth RA, Greer SL, Albert JM, et al. Out of pocket spending and medication adherence among dialysis patients in 12 countries. Health Aff (Millwood). 2008;27:89-102.
25. Hsu J, Price M, Huang J, et al. Unintended consequences of caps on Medicare drug benefits. N Engl J Med. 2006;354:2349-2359.
26. Tamblyn R, Laprise R, Hanley JA, et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA. 2001;285:421-429.
27. Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med. 2006;166:1836-1841.
28. Patel BV, Remigio-Baker RA, Thiebaud P, et al. Improved persistence and adherence to diuretic fixed-dose combination therapy compared to diuretic monotherapy. BMC Fam Pract. 2008;9:61.
29. Doshi JA, Zhu J, Lee BY, et al. Impact of a prescription copayment increase on lipid-lowering medication adherence in veterans. Circulation. 2009;119:390-397.
30. The Pharmacy Quality Alliance. Proportion of days covered: antidepressant continuation phase. www.pqaalliance.org/files/Nov2008Meeting Materials/MENTALHEALTHAntidepressContinuationPDCMeasure Con cept.doc. Accessed February 20, 2009.
31. Centers for Medicare & Medicaid Services. Medicare Part D benefit parameters for standard benefit: annual adjustments for 2007. May 22, 2006. www.cms.hhs.gov/MedicareAdvtgSpecRateStats/Downloads/2007- Part-D-Parameter- Update.pdf. Accessed September 8, 2009.
32. Centers for Medicare & Medicaid Services. Notification of changes in Medicare Part D payment for calendar year 2008. www.cms.hhs.gov/ MedicareAdvtgSpecRateStats/Downloads/PartDannouncement2008.pdf. April 2, 2007. Accessed September 8, 2009.
33. Biotechnology Industry Organization. Medicare Part D plans deliver significant savings on innovative, breakthrough medicines. www.bio.org/ healthcare/medicare/BIOPricingSurvey.pdf. Accessed February 20, 2009.
34. Nayeem AI, Chertow GM. Lessons for Medicare Part D in the hemodialysis community. BMC Nephrol. 2006;7:11.
35. Zou G. A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004;159:702-706.
36. US Renal Data System. USRDS 2008 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. 2008. www.usrds.org/2008/pdf/V2-11-2008.pdf. Accessed January 21, 2009.
37. Karamanidou C, Clatworthy J, Weinman J, Horne R. A systematic review of the prevalence and determinants of nonadherence to phosphate binding medication in patients with end-stage renal disease. BMC Nephrol. 2008;9:2.
38. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare costs. Med Care. 2005;43:521-530.
39. Svarstad BL, Shireman TI, Sweeney JK. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv. 2001;52:805-811.
40. Balkrishnan R, Rajagopalan R, Camacho FT, et al. Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus. Clin Ther. 2002;25:2958-2971.
41. 41. Patel UD, Davis MM. Falling into the doughnut hole: drug spending among beneficiaries with end-stage renal disease under Medicare Part D plans. J Am Soc Nephrol. 2006;17:2546-2553.